This Amendment No. 5 relates to the Common Stock of Dynavax Technologies Corporation and amends the
initial statement on Schedule 13D filed by the Reporting Persons on August 22, 2019, as amended by Amendment No. 1 filed on March 12, 2020, Amendment No. 2 filed on May 28, 2020, Amendment No. 3 filed on June 11,
2021 and Amendment No. 4 filed on August 11, 2021 (the Initial Statement and, as further amended by this Amendment No. 5, the Schedule 13D). Capitalized terms used but not defined herein shall have the meanings
ascribed to them in the Initial Statement.
Item 5.
|
Interest in Securities of the Issuer
|
Item 5 of the Initial Statement is hereby amended and restated as follows:
The information set forth in or incorporated by reference in Items 2, 3 and 4 and on the cover pages of this Schedule 13D is incorporated by reference in its
entirety into this Item 5.
(a), (b)
|
As of the date hereof, (i) BC LS holds 7,634,045 shares of Common Stock, representing approximately 6.4%
of the outstanding Common Stock of the Issuer, and BCIP LS holds 780,955 shares of Common Stock, representing approximately 0.7% of the outstanding Common Stock of the Issuer. As a result of the foregoing and the relationships described in Item 2 of
this Schedule 13D, the Reporting Persons may be deemed to collectively beneficially own 8,415,000 shares of Common Stock as of the date hereof, representing approximately 7.1% of the outstanding Common Stock of the Issuer.
|
The calculation of the beneficial ownership of the Reporting Persons is based on (i) 114,760,092 shares of Common Stock issued and outstanding,
as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed with the Securities and Exchange Commission on August 4, 2021 and (ii) 4,140,000 shares of
Common Stock issued by the Issuer in connection with the conversion of shares of Series B Preferred Stock held by the Reporting Persons subsequent to August 4, 2021.
(c)
|
On August 27, 2021, the Reporting Persons converted an aggregate of 1,891 shares of Series B Preferred
Stock into an aggregate of 1,891,000 shares of Common Stock, consisting of 1,715 shares of Series B Preferred Stock held by BC LS and 176 shares of Series B Preferred Stock held by BCIP LS.
|
Also on August 27, 2021, the Reporting Persons sold an aggregate of 2,000,000 shares of Common Stock at a price of $16.25 per share
pursuant to Rule 144 under the Securities Act of 1933, as amended, for aggregate consideration of $32,500,000. In the transaction, BC LS sold 1,814,290 shares of Common Stock and BCIP LS sold 185,710 shares of Common Stock.
(d)
|
Except as otherwise described in this Item 5, no one other than the Reporting Persons has the right to receive,
or the power to direct the receipt of, dividends from, or the proceeds from the sale of, any of the Common Stock beneficially owned by the Reporting Persons as described in this Item 5.
|